{"nctId":"NCT00124072","briefTitle":"Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine","startDateStruct":{"date":"1998-07"},"conditions":["Cardiovascular Disease"],"count":12064,"armGroups":[{"label":"Simvastatin 20 mg + folic acid and B12","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Simvastatin 20 mg daily","Dietary Supplement: Folic acid 2 mg + vitamin B12 1 mg daily"]},{"label":"Simvastatin 80 mg + folic acid and B12","type":"ACTIVE_COMPARATOR","interventionNames":["Dietary Supplement: Folic acid 2 mg + vitamin B12 1 mg daily","Drug: Simvastatin 80 mg daily"]},{"label":"Simvastatin 20 mg + placebo","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Simvastatin 20 mg daily","Drug: Placebo"]},{"label":"Simvastatin 80 mg + placebo","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Simvastatin 80 mg daily","Drug: Placebo"]}],"interventions":[{"name":"Simvastatin 20 mg daily","otherNames":[]},{"name":"Folic acid 2 mg + vitamin B12 1 mg daily","otherNames":[]},{"name":"Simvastatin 80 mg daily","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Prior myocardial infarction\n* Statin therapy indicated\n* No clear indication for folic acid\n\nExclusion Criteria:\n\n* No clear contraindication to study treatments\n* Screening plasma total cholesterol \\<3.5 mmol/l in patient already on statin therapy, or \\<4.5 mmol/l in patient not on statin therapy\n* Chronic liver disease\n* Severe renal disease or evidence of renal impairment\n* Inflammatory muscle disease\n* Concurrent treatment with fibrates or high-dose niacin\n* Concurrent treatment with cyclosporin (or condition likely to result in organ transplantation and the need for cyclosporin), nefazodone, methotrexate, systemic azole antifungal or systemic macrolide antibiotics\n* Child bearing potential\n* No other predominant medical problem (other than coronary heart disease \\[CHD\\]) which might limit compliance with 5 years of study treatment","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Major Vascular Events (MVE)","description":"Major vascular events (MVE) defined as major coronary events (MCE \\[non-fatal MI, coronary death or coronary revascularisation\\]), non-fatal or fatal stroke, or peripheral revascularization (peripheral artery angioplasty or arterial surgery, including amputations), during the scheduled study treatment period.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1553","spread":null},{"groupId":"OG001","value":"1477","spread":null},{"groupId":"OG002","value":"1537","spread":null},{"groupId":"OG003","value":"1493","spread":null}]}]}]},{"type":"SECONDARY","title":"MVEs Separately in Year 1 and in Later Years","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"MVEs in Patients Subdivided Into 3 Groups by Baseline Low-density Lipoprotein (LDL)","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"MVEs in Presence and Absence of the Other Factorial Treatment","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Major Coronary Events","description":"Non-fatal MI, coronary death or coronary revascularisation","paramType":"NUMBER","dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Total Strokes","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":5037,"n":6033},"commonTop":["Other and unspecified symptom or problem","Tiredness or lethargy","Abdominal pain or indigestion"]}}}